HMGB1 and glioblastoma: We first stained for HMGB1 and HSP70 in the group of mice that received nivolumab monotherapy, which in a clinical trial failed to result in the improvement of the GBM patient’s overall survival (Checkmate-548 clinical trial, NCT02667587).